Claims for Patent: 6,350,784

Summary for Patent: 6,350,784

Title:	Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
Abstract:	An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.
Inventor(s):	Squires; Meryl (Willowbrook, IL)
Assignee:	Squires; Meryl J. (Barrington Hills, IL)
Application Number:	08/824,041
Patent Claims:	1. A method for use in treating human immunedeficiency virus, comprising the steps of: systemically applying an antimicrobial compound with a syringe into a rectal canal or vagina of a person infected with human immunedeficiency virus; said antimicrobial compound comprises by weight: from about 40% to about 60% of a phytochemical concentrate of herbaceous botanicals consisting of Commiphora myrrha and Echinacea purpurea; said phytochemical concentrate of Commiphora myrhha and Echinacea purpurea providing antimicrobial isolates; from about 20% to about 60% sterile water providing a diluent and carrier for said phytochemical concentrate; from about 0.02% to about 0.30% ammonium salt surfactant comprising benzalkonium chloride; from about 2% to about 12% folic acid providing a nutrient; and said folic acid cooperating with said Commiphora myrrha and said Echinacea purpurea to treat human immunedeficiency virus; applying said antimicrobial compound in sufficient concentration and a sufficient period of time to decrease human immunedeficiency virus in the patient; controlling viral load; and said antimicrobial isolates of said phytochemical concentrate, comprises by weight based upon the total weight of the medical composition: from about 0.3% to about 9% echinacoside; from about 0.1% to about 7% PSI (4-O-methylglucoronoarabinoxylan, Mr 35 kD) and PSI (acid rhamnoarabinogalactan, Mr 450 kD); from about 0.1% to about 10% cynarin (1,5-di-o-caffeoylquinic acid) and chioric acid (2,3-O-di-caffeoyltartaric acid) and derivatives thereof; from about 0.2% to about 4% echinolone; from about 0.2% to about 8% echinacin B; from about 0.1 to about 6% echinaceine; from about 2% to about 7% anthonocyanins comprising cynanidin 3-O-B-D-glucopyranoside and 3-O-(6-O-malonyl)-B-D-glucopyranoside; from about 0.01% to about 0.06% pyrrolizidine alkaloids comprising tussilagine and isotussilagine; from about 0.003% to about 0.009% isomeric dodeca isobutyalamides and tetroenoic acid; and Commophora myrrha phytochemicals comprising members selected from the group consisting of: caryophylenes, sequiterpenes, curzerenone, dihydro fuanodien-6-one; 2-methoxyfuradine, elemol, lyndesterene, acetic acid, alpha-amyrone, arabinose, alpha-bisabolene, gamma-bisabolene, cadinene, campesterol, cholesterol, cinnamaldehyde, commiferin, alpha-commiphoric acid, beta-commiphoric acid, gama-commiphoric acid, commiphorinic acid, m-cresol, cumic alcohol, cuminaldehyde, dipentene, elemol, 3-epi-alpha-amyrin, eugenol, furanodiene, furanodienone, galactose, gum, heerabolene, alpha-heerabomyrrhol, beta-heerabomyrrhol, heeraboresene, limonene, 4-O-methyl-glucuronic acid, n-nonacesane, beta-sitosterol, xylose. 2. A method for use in treating human immunedeficiency virus, comprising the steps of: systemically applying an antimicrobial compound with a syringe into a rectal canal or vagina of a person infected with human immunedeficiency virus; said antimicrobial compound comprises by weight: from about 40% to about 60% of a phytochemical concentrate of herbaceous botanicals consisting of Commiphora myrrha and Echinacea purpurea; from about 20% to about 60% sterile water providing a diluent and carrier for said phytochemical concentrate; from about 2% to about 12% folic acid providing a nutrient; and said folic acid cooperating with said Commiphora myrrha and said Echinacea purpurea to treat human immunedeficiency virus; applying said antimicrobial compound in sufficient concentration and a sufficient period of time to decrease human immunedeficiency virus in the patient; controlling viral load; and said antimicrobial isolates of said phytochemical concentrate, comprises by weight based upon the total weight of the medical composition: from about 0.3% to about 9% echinacoside; from about 0.1% to about 7% PSI (4-O-methylglucoronoarabinoxylan, Mr 35 kD) and PSI (acid rhamnoarabinogalactan, Mr 450 kD); from about 0.1% to about 10% cynarin (1,5-di-o-caffeoylquinic acid) and chioric acid (2,3-O-di-caffeoyltartaric acid) and derivatives thereof; from about 0.2% to about 4% echinolone; from about 0.2% to about 8% echinacin B; from about 0.1 to about 6% echinaceine; from about 2% to about 7% anthonocyanins comprising cynanidin 3-O-B-D-glucopyranoside and 3-O-(6-O-malonyl)-B-D-glucopyranoside; from about 0.01% to about 0.06% pyrrolizidine alkaloids comprising tussilagine and isotussilagine; from about 0.003% to about 0.009% isomeric dodeca isobutyalamides and tetroenoic acid; and Commophora myrrha phytochemicals comprising members selected from the group consisting of: caryophylenes, sequiterpenes, curzerenone, dihydro fuanodien-6-one; 2-methoxyfuradine, elemol, lyndesterene, acetic acid, alpha-amyrone, arabinose, alpha-bisabolene, gamma-bisabolene, cadinene, campesterol, cholesterol, cinnamaldehyde, commiferin, alpha-commiphoric acid, beta-commiphoric acid, gama-commiphoric acid, commiphorinic acid, m-cresol, cumic alcohol, cuminaldehyde, dipentene, elemol, 3-epi-alpha-amyrin, eugenol, furanodiene, furanodienone, galactose, gum, heerabolene, alpha-heerabomyrrhol, beta-heerabomyrrhol, heeraboresene, limonene, 4-O-methyl-glucuronic acid, n-nonacesane, beta-sitosterol, xylose.

Details for Patent 6,350,784

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2016-02-12